Arkolith/Insider Trading/SPRO/Form 4

Rajavelu Esther

See RemarksSpero Therapeutics, Inc. (SPRO) · full profile →Form 4 · filed Feb 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$41K
Net Open-Market Flow
-$41K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2026Sell(S)18K$2.20$41K1.1M
Feb 2, 2026Grant(A)249K—$01.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 2, 2026Grant(A)498K—$0498K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-038184) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML